Industry

PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially registrational Phase 2 trial Initial median overall survival of 13.2 months observed in the combination cohort at the proposed Phase 2 dose, exceeding expected late-line relapsed/refractory setting … [Read more…]

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–(BUSINESS WIRE)–Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design, develop, and operate a portfolio of digital and AI solutions aimed at improving efficiency and automating complex business processes. The launch of this new company is the direct outcome of a year … [Read more…]

Natera Acquires Foresight Diagnostics

Expands Natera’s lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera’s portfolio of >500 issued or pending patents Accelerates Natera’s expansion into lymphoma, where Foresight has developed a strong clinical position AUSTIN, Texas & BOULDER, Colo.–(BUSINESS … [Read more…]

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body

Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the … [Read more…]

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a consistent safety profile Breyanzi is now the only CAR T cell therapy approved by the FDA for five cancer types, the most of any CD19-directed CAR T cell therapy PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #Breyanzi—Bristol Myers Squibb … [Read more…]

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

BEIJING–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class … [Read more…]

VALVOSOFT®, the First Non-Invasive Treatment for Severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave Receives CE Marking

LEVALLOIS-PERRET, France–(BUSINESS WIRE)–#AorticStenosis–Cardiawave, a pioneering medtech company developing non-invasive ultrasound therapy (NIUT) for aortic stenosis, has received CE Certificate for Valvosoft®, the world’s first non-invasive therapeutic alternative to treat Severe Symptomatic Aortic Stenosis (sSAS), a serious, degenerative and fast-growing disease due to population aging, which remains without a solution for many patients around the world. … [Read more…]

SullivanCotter and Lotis Blue Consulting Identify Competencies Defining the Future-Ready Health System CEO

CHICAGO–(BUSINESS WIRE)–#CEOSuccession—SullivanCotter, the nation’s leading independent consulting firm in the assessment and development of total rewards programs, workforce solutions, and data products for health care and not-for-profits, and its strategic partner Lotis Blue Consulting have released The Future-Ready Health System CEO: The Competencies and Attributes That Will Define Leadership in the Next Era of Health … [Read more…]

Hims & Hers Now Serving Customers in Canada

Follows strategic acquisition of Livewell, a trusted Canadian digital health platform for weight loss care MONTREAL–(BUSINESS WIRE)–Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, is now serving customers in Canada. This entry follows the recent acquisition of Livewell, a trusted Canadian digital health platform focused on … [Read more…]

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

The companies have entered into a new collaboration where LabGenius Therapeutics will apply its ML-driven antibody discovery platform (EVA™) to optimise potential therapeutic NANOBODY® proteins for multiple new targets LONDON–(BUSINESS WIRE)–#AI—LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with … [Read more…]